Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium

Study Status

Open to Enrollment

Study Description

This clinical trial is for men and women with multiple myeloma that has either come back after treatment (relapsed) or has not responded to other treatments (refractory).

The purpose of the study is to see whether pomalidomide reduces the number of myeloma cells in the bones, and to determine the best way to use pomalidomide in patients with myeloma. To do this, the investigators want to compare two types of treatment using pomalidomide. All patients start by receiving 4 cycles of pomalidomide and dexamethasone. After 4 cycles, study participants will be randomly assigned to one of two treatment groups:

  • Group 1: Participants will undergo an autologous stem cell transplant followed by pomalidomide maintenance therapy
  • Group 2: Participants will continue to receive pomalidomide and dexamethasone for 5 cycles followed by pomalidomide maintenance therapy

Pomalidomide inhibits the growth of myeloma cells and was recently approved by the FDA for treating relapsed/refractory myeloma. Dexamethasone is approved by the FDA and is often used in combination with other drugs to treat multiple myeloma.

Participants will be in the study for up to 2 years as long as they respond to therapy and do not experience unacceptable side effects. At the end of the study, the two groups will be compared to see if there is a difference in disease outcome.

Key eligibility:

  • Men and women age 18 and older
  • Relapsed/refractory multiple myeloma
  • Must have been on a minimum of 3 months of maintenance therapy prior to disease progression
  • Detailed eligibility reviewed when you contact the study team

Linda Tegnestam, R.N.
Phone: (212) 746-1480

Kathleen Pogonowski, R.N.
Phone: (212) 746-6738

Disease Status and/or Stage

Relapsed/Refractory Multiple Myeloma


Celgene; Memorial Sloan Kettering Cancer Center

Principal Investigator

Tomer Mark, M.D.


Protocol ID

WCMC IRB #1303013631

Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries please e-mail:
Erica Bersin
Manager, Subject Recruitment & Communications
(646) 962-8232

To locate contact information for specific studies, please click the disease areas in the left side navigation and click the study title. There you will find study contact details.

Top of page